Drug Trial Radar · NCT07712731
HPP737 in Adult Patients With Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
607
Actual
Start
Apr 18, 2025
Primary completion
Apr 1, 2026
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- Newsoara Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to an active control drug, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score and other standardized assessments? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to an active control drug (a positive drug comparator) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis. This is a multicenter, randomized, double-blind, double-dummy, active-controlled Phase III clinical trial. Participants will: Take drug HPP737 or an active control drug orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) The trial plans to enroll approximately 606 participants across about 61 centers in China. Eligible participants are adults aged 18 years and older with a confirmed diagnosis of stable moderate-to-severe plaque psoriasis for at least 6 months.
Conditions
- Psoriasis
Interventions
HPP737Drug
HPP737 capsules for oral administration.
Placebo matching HPP737Drug
Placebo capsules matching HPP737 for oral administration.
ApremilastDrug
Apremilast tablets for oral administration.
Placebo matching ApremilastDrug
Placebo tablets matching Apremilast for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75);Time frame: From enrollment to end of treatment at 16 weeks
- To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)"Time frame: From enrollment to end of treatment at 16 weeks
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
Inner Mongolia Baogang Hospital
Baotou, China
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Beijing Tsinghua Changgung Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Cangzhou People's Hospital
Cangzhou, China
The Second Hospital of Jilin University
Changchun, China
Changde First People's Hospital
Changde, China
Third Xiangya Hospital of Central South University
Changsha, China
The Second People's Hospital of Changzhi
Changzhi, China
Affiliated Hospital of Chengde Medical College
Chengde, China
Chengdu Second People's Hospital
Chengdu, China
Sichuan Provincial People's Hospital
Chengdu, China
First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Dalian Dermatology Hospital
Dalian, China
Dermatology Hospital, Southern Medical University
Guangzhou, China
Guangzhou First People's Hospital
Guangzhou, China
Zhujiang Hospital of Southern Medical University
Guangzhou, China
Affiliated Hospital of Guilin Medical University
Guilin, China
Hainan Fifth People's Hospital
Haikou, China
Hangzhou First People's Hospital
Hangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
Dermatology Hospital, Shandong First Medical University
Jinan, China
Jinan Central Hospital
Jinan, China
Shandong Provincial Hospital
Jinan, China
Jingzhou Central Hospital
Jingmen, China
The First Affiliated Hospital of Kunming Medical University
Kunming, China
Lianyungang First People's Hospital
Lianyungang, China
Liaocheng People's Hospital
Liaocheng, China
Jiangxi Provincial Dermatology Hospital
Nanchang, China
Second Affiliated Hospital of Nanchang University
Nanchang, China
Hospital of Dermatology, Chinese Academy of Medical Sciences
Nanjing, China
First Affiliated Hospital of Ningbo University
Ningbo, China
Qingdao Traditional Chinese Medicine Hospital (Hai Ci Hospital)
Qingdao, China
Qujing First People's Hospital
Qujing, China
Huashan Hospital, Fudan University
Shanghai, China
Shanghai Skin Disease Hospital
Shanghai, China
Affiliated Central Hospital of Shenyang Medical College
Shengyang, China
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.